Historique
Périodique
Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts
(Effets de la buprenorphine et de la naloxone sur des toxicomanes aux opiacés stabilisés par la morphine)
Auteur(s) :
FUDALA, P. J. ;
YU, E. ;
McFADDEN, W. ;
BOARDMAN C. ;
CHIANG, C. N.
Année
1998
Page(s) :
1-8
Langue(s) :
Anglais
ISBN :
0376-8716
Refs biblio. :
36
Domaine :
Drogues illicites / Illicit drugs
Thésaurus mots-clés
BUPRENORPHINE
;
NALOXONE
;
MORPHINE
;
ANTAGONISTE
;
VOIE INTRAVEINEUSE
;
SYNDROME DE SEVRAGE
;
COMPARAISON
Note générale :
Drug and Alcohol Dependence, 1998, 50, (1), 1-8
Résumé :
FRANÇAIS :
10 toxicomanes dépendants d'opiacés et stabilisés par la morphine, ont reçu un placebo ou de la morphine ou de la buprénorphine ou une association buprénorphine/naloxone ou de la naloxone. La naloxone et l'association buprénorphine/naloxone entrainent des effets de syndrome de sevrage d'opiacés, mesurés sur l'échelle CINA (Clinical Institute Narcotic Assessement Scale). L'association buprenorphine/naloxone dans un rapport 4/1, produit des effets antagonistes des opiacés qui devraient limiter son utilisation potentielle par des héroïnomanes.
ENGLISH :
The present study, conducted as part of the development of a buprenorphine:naloxone combination product, was designed to evaluate the individual and combined effects of intravenously administered buprenorphine and naloxone. This in-patient trial used a randomized, double-blind, crossover design. Ten opioid-dependent male subjects were stabilized and maintained on morphine, 15 mg given intramuscularly four times daily. Then, at 48- to 72-h intervals, subjects received one of the following by intravenous injection: (1) placebo, (2) morphine 15 mg, (3) buprenorphine 2 mg, (4) buprenorphine 2 mg:naloxone 0.5 mg, and (5) naloxone 0.5 mg. Both naloxone and buprenorphine:naloxone produced significant (PB0.005) opioid withdrawal effects compared to placebo as assessed with the CINA scale, an instrument which utilizes subject- and observer-reported, as well as physiological parameters. The combination of buprenorphine with naloxone in a 4:1 ratio produced opioid antagonist-like effects which should limit its potential for intravenous abuse by opioid addicts.
10 toxicomanes dépendants d'opiacés et stabilisés par la morphine, ont reçu un placebo ou de la morphine ou de la buprénorphine ou une association buprénorphine/naloxone ou de la naloxone. La naloxone et l'association buprénorphine/naloxone entrainent des effets de syndrome de sevrage d'opiacés, mesurés sur l'échelle CINA (Clinical Institute Narcotic Assessement Scale). L'association buprenorphine/naloxone dans un rapport 4/1, produit des effets antagonistes des opiacés qui devraient limiter son utilisation potentielle par des héroïnomanes.
ENGLISH :
The present study, conducted as part of the development of a buprenorphine:naloxone combination product, was designed to evaluate the individual and combined effects of intravenously administered buprenorphine and naloxone. This in-patient trial used a randomized, double-blind, crossover design. Ten opioid-dependent male subjects were stabilized and maintained on morphine, 15 mg given intramuscularly four times daily. Then, at 48- to 72-h intervals, subjects received one of the following by intravenous injection: (1) placebo, (2) morphine 15 mg, (3) buprenorphine 2 mg, (4) buprenorphine 2 mg:naloxone 0.5 mg, and (5) naloxone 0.5 mg. Both naloxone and buprenorphine:naloxone produced significant (PB0.005) opioid withdrawal effects compared to placebo as assessed with the CINA scale, an instrument which utilizes subject- and observer-reported, as well as physiological parameters. The combination of buprenorphine with naloxone in a 4:1 ratio produced opioid antagonist-like effects which should limit its potential for intravenous abuse by opioid addicts.
Affiliation :
Department of Psychiatry, University of Pennsylvania School of Medicine – Department of Veterans Affairs Medical Center, Philadelphia, PA, USA